We propose that ALK7 signaling contributes to diet-induced catecholamine resistance in adipose tissue, and suggest that ALK7 inhibitors may have therapeutic value in human obesity. This evidence concerns the gene ACVR1C and obesity due to melanocortin 4 receptor deficiency.